Follow this innovation
[ via 
] [?]
Multiple Acting Anti-angiogenic and Cytotoxic Compounds
Duquesne University of the Holy Spirit
posted on 03/03/2009
A Professor of Medicinal Chemistry in the Graduate School of Pharmaceutical Sciences at Duquesne University who is an authority in the development of pyrimidine derivatives and their application as powerful anti-tumor agents, has invented a series of compounds and their pharmaceutically acceptable salts described in US patent 6,770,652. These compounds target multiple tumor growth pathways, such as the inhibition of receptor tyrosine kinases (RTK), and act to inhibit angiogenesis typically associated with tumor growth and metastatic potential.
Suggested Uses
Cancer therapy, Anti-angiogenic Compound
Advantages
These compounds target multiple tumor growth pathways by inhibiting receptor tyrosine kinase which will inhibit angiogenesis associated with growth and metastatic potential.
Detailed Description
A significant number of promising compounds are currently in clinical trials which target cellular pathways implicated in the growth and proliferation of tumors. A number of these compounds such as SU6668 , ZD64742, and PTK787/ZK2225843 specifically target receptor tyrosine kinases and show marked anti-angiogenic activity. Angiogenesis, the process by which tumors recruit or develop new micro vasculature is an important process in tumor growth and the development of metastatic activity. Compounds which inhibit angiogenesis have the property to limit tumor growth, inhibit metastasis and provide therapies which can improve patient prognosis.
Representative compounds covered under this invention have been tested for angiogenic activity using the chorioallantoic membrane assay (CAM), and for RTK inhibition (EGFR, Flk-1, Flt-1). Many of the compounds tested show multiple modes of action as measured by IC50.
File Number: 6,770,652
Web site: http://www.research.duq.edu
Disease: Cancer
| Patent Number(s): | 6770652 |
|---|
This innovation currently is not available for online licensing. Please contact Alan Seadler at Duquesne University of the Holy Spirit for more information.
request more info
ProfileFind more innovations
